Cognition Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-8.6%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.32next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 5 Nov 2026 |
| Topline Data Readout from Phase 2 START Study in Early Alzheimer's | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
Cash Runway Horizon Quarterly2KTarget: Q2 2027
Remaining National Institute on Aging (NIA) Grant Funding Quarterly25.6MTarget: Fully utilize to fund START trial
START Phase 2 Trial Enrollment Annually545.0
Watch Items
- FDA Division of Psychiatry Meeting Minutes for Zervimesine in DLB PsychosisTrigger: Receipt of official minutes outlining registrational Phase 3 pathAction: Finalize Phase 3 trial design and initiate clinical site preparation
- Topline Data Readout from the Phase 2 START Study in Early Alzheimer's DiseaseTrigger: Release of topline cognitive and biomarker data in 2027Action: Evaluate efficacy signals to determine Phase 3 registrational strategy in AD
- Cash Reserves and Capital RunwayTrigger: Cash balance falling below $15 millionAction: Execute additional capital raises, ATM offerings, or secure strategic partnerships
Research as of 19 Jun 2026